Rocket One Inc. (RKTO) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While RKTO currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.66) and Max Pain ($0.55) forces dealer call-delta covering toward $2.57.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Rocket One Inc. (RKTO) dropped -4.96% to $0.52, trading at 3% of its 52-week range ($0.47 – $2.45). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Rocket One Inc. ("Rocket One" or the "Company") today announced a sponsored research agreement with Virginia Commonwealth University ("VCU") to develop and demonstrate magnetic computing devices targeting a critical chal
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RKTO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RKTO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Rocket One Inc. (RKTO) ranks #524 by composite RQD confidence (44/100, grade D) and #871 by equity capitalization ($12.8M). Within this direct 5-issuer industry benchmark cohort, RKTO leads on earnings valuation at N/A trailing P/E, while RKTO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RKTO currently leads its immediate peer cohort in composite quantitative strength at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RKTO
ACTIVE
Rocket One Inc. | D | 44/100 | — | — | -35.0% | -4.96% | $12.8M | Benchmark Subject |
| LPCN Lipocine Inc. | D- | 37/100 | — | — | -35.0% | +0.66% | $12.5M | /lpcn-vs-rkto → |
| KTTA Pasithea Therapeutics Corp. | D | 44/100 | — | — | -35.0% | -5.95% | $12.3M | /ktta-vs-rkto → |
| DARE Dare Bioscience Inc. | D | 44/100 | — | 71.3% | -35.0% | +0.22% | $13.4M | /dare-vs-rkto → |
| HIND Vyome Holdings Inc. | D- | 35/100 | — | 68.4% | -35.0% | +1.74% | $12.3M | /hind-vs-rkto → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rocket One Inc. (RKTO) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$12.5M, operating cash flow of -$9.8M, and free cash flow of -$9.8M (-40.5% YoY). On the balance sheet, RKTO closed FY2025 with $7.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$12.5M | -$9.8M | -$9.8M | $7.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$8.2M | -$7.0M | -$7.0M | $7.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$8.1M | -$8.4M | -$8.4M | — | — |
As of 2026-11-01, Rocket One Inc. (NASDAQ: RKTO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $0.52 (-4.96% 1D, market cap $12.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RKTO ranks #524 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RKTO carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LPCN (Lipocine Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $12.5M) and KTTA (Pasithea Therapeutics Corp.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M). Among the 5-stock peer group, RKTO leads on earnings multiple (N/A) while RKTO leads on capital efficiency (-35.0% ROIC).
Per RKTO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001711786), Rocket One Inc. generated $0 in revenue, -$12.5M in net income, and -$9.8M in free cash flow against $7.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
RKTO last traded at $0.52 (-4.96% on volume of 131,506 shares), positioning the stock -21.21% below its 50-day simple moving average ($0.66) and -38.82% below its 200-day simple moving average ($0.85). Across its 52-week range of $0.47 to $2.45, RKTO sits at the 2.5% percentile with a 14-day RSI of 33.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.59).
Why RKTO Stock dropped -4.96% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.